Collectively, these results strongly advocate for A8 and A3/8 as promising therapeutic avenues, not only for specific genetic conditions such as APOA5 or CREBH deficiency but also for a broader patient population with hyperlipidemia. Here, APOA5 is linked to hyperlipidemia.